Key Takeaways
- Precision oncology uses a tumor’s DNA or genetic alterations to find targeted therapies that specifically benefit a unique patient.
- Lung cancer patients are seeing significant advances in targeted therapies, thanks to precision oncology.
- Oncologists with Lipson Cancer Institute offer precision oncology for eligible patients and are taking part in clinical trials.
Discover the advanced cancer care, innovative treatment options, and personalized support services we offer all our patients at Lipson Cancer Institute.
Precision oncology is a newer branch of cancer treatment that bases a patient’s treatment plan on their tumor’s unique molecular features. Before precision oncology, more traditional cancer treatments would focus on where the cancer started in the body or how it looked under the microscope.
By identifying the biomarkers of the tumor, oncologists can diagnose, risk stratify, and tailor cancer treatments and medications even more precisely for each patient.
We asked Rachel David, MD, Attending Medical Oncologist & Hematologist with Rochester Regional Health’s Lipson Cancer Institute, to explain how precision oncology works, which cancers are seeing breakthrough treatments thanks to this new branch of treatment, and how Lipson Cancer Institute helps patients with cancer through their cancer journeys.
Precision cancer treatment vs. traditional cancer treatment
For a long time, medical oncologists have determined how they treat cancers by where they started in the body.
Precision oncology takes in as much information as possible about the tumor itself. This means analyzing the tumor for its DNA signature and treating that part of the cancer instead.
Oncologists take a biopsy of the tumor, then use a process called immunohistochemistry to determine the presence or absence of certain proteins or other antigens that are related to the tumor. A similar process called next-generation sequencing (NGS) is also often used. NGS takes longer because it analyzes the DNA of the tumor itself to identify genetic mutations or alterations that can be targeted.
Based on the results of the pathology results, the oncology team will determine if there are any existing targeted therapies that can be used. The type of targeted therapy depends on the presence or absence of specific biomarkers.
Precision oncology now allows us to classify some cancers according to biomarkers, in addition to their organ of origin. We now have cancer therapies that are approved based on biomarker alone — for example, pembrolizumab is a type of immunotherapy that is approved for mismatch-repair deficient advanced cancers regardless of where they started in the body.
Which types of cancers see the best outcomes from precision oncology?
The field of precision oncology has seen the most advances for lung cancer, specifically a subtype called non-small cell lung cancer.
Specific subtypes of lung cancer now have targeted therapies, including these genetic mutations:
- ALK
- BRAF
- EGFR
- HER2
- KRAS G12C
- MET
- NRG1
- RET
- ROS1
“Patients with incurable ALK-rearranged lung cancers can now expect to live for many years with great quality of life from targeted therapy,” Dr. David said.
Breast cancer and acute leukemia have also seen significant progress, thanks to precision oncology.
How Lipson Cancer Institute is using precision oncology
At Lipson Cancer Institute, our medical oncology providers offer targeted therapies through precision oncology for eligible patients.
Each patient’s cancer care team needs to consider several factors before moving ahead with a precision oncology approach, including the type of cancer being treated, how long a patient can wait for test results before determining the course of treatment, and insurance coverage for the targeted therapy.
Not only are patients with Lipson Cancer Institute are able to receive treatment through this modern cancer care approach, but they also have access to precision oncology clinical trials.
The MyeloMATCH clinical trial program, with Maria Sbenghe, MD, as our local principal investigator, is a precision-medical clinical trial for patients with newly diagnosed myelodysplastic syndromes and acute myeloid leukemia.
Using biomarkers obtained from each patient’s biopsied tissue, oncologists then identify clinical trials and match therapies that are uniquely suited for the patient to give them the best possible outcome.
“This is a coordinated nationwide effort to personalize therapy for these patients based on real-time molecular profiling,” Dr. David said. “We are proud to offer this to our patients locally.”
Are You Eligible For Lung Cancer Screening?
Lung cancer is the leading cause of cancer deaths in the U.S. but finding cancer early often means we can treat it. Take our health risk assessment and see if you are eligible for our non-invasive lung cancer screening.
